Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125765141 | 12576514 | 1 | I | 20160714 | 20160720 | 20160720 | EXP | SG-MYLANLABS-2016M1029882 | MYLAN | RAYMOND YCF, GLENDA CSL, MENG LK. EFFECTS OF HIGH DOSES OF VITAMIN C ON CANCER PATIENTS IN SINGAPORE: NINE CASES. INTEGR-CANCER-THER 2016;15(2):197-204. | 0.00 | Y | 0.00000 | 20160720 | OT | SG | SG |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125765141 | 12576514 | 1 | PS | ASCORBIC ACID. | ASCORBIC ACID | 1 | Intravenous drip | U | U | 0 | INJECTION | ||||||||
| 125765141 | 12576514 | 2 | SS | GEFITINIB | GEFITINIB | 1 | Unknown | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125765141 | 12576514 | 1 | Lung carcinoma cell type unspecified stage IV |
| 125765141 | 12576514 | 2 | Lung carcinoma cell type unspecified stage IV |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125765141 | 12576514 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125765141 | 12576514 | Abasia | |
| 125765141 | 12576514 | Dry mouth |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125765141 | 12576514 | 1 | 20131116 | 0 |